Perifosine

Generic Name
Perifosine
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C25H52NO4P
CAS Number
157716-52-4
Unique Ingredient Identifier
2GWV496552
Background

Perifosine is a novel alkylphospholipid with antiproliferative properties attributed to protein kinase B inhibition.

Indication

Investigated for use/treatment in solid tumors, multiple myeloma, leukemia (unspecified), lung cancer, and brain cancer.

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Phase I Study of Perifosine + Sorafenib for Patients With Advanced Cancers

Phase 1
Completed
Conditions
Renal Cancer
Tumors
Interventions
Drug: Perifosine
Drug: Sorafenib
First Posted Date
2006-11-14
Last Posted Date
2014-02-19
Lead Sponsor
AEterna Zentaris
Target Recruit Count
30
Registration Number
NCT00398814

Perifosine + Sunitinib Malate for Patients With Advanced Cancers

Phase 1
Completed
Conditions
Renal Cancer
GIST
Interventions
Drug: Perifosine
Drug: Sunitinib Malate
First Posted Date
2006-11-14
Last Posted Date
2014-02-19
Lead Sponsor
AEterna Zentaris
Target Recruit Count
15
Registration Number
NCT00399152

A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenström's Macroglobulinemia

Phase 2
Completed
Conditions
Waldenström's Macroglobulinemia
Interventions
Drug: Perifosine
First Posted Date
2006-11-14
Last Posted Date
2018-03-15
Lead Sponsor
AEterna Zentaris
Target Recruit Count
37
Registration Number
NCT00398710
Locations
🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Phase I Trial of Paclitaxel With Perifosine

Phase 1
Completed
Conditions
Neoplasms
First Posted Date
2006-11-14
Last Posted Date
2014-02-13
Lead Sponsor
AEterna Zentaris
Target Recruit Count
24
Registration Number
NCT00399126
Locations
🇺🇸

AOI Pharmaceuticals Investigative Site, Johnson City, Tennessee, United States

Phase I Trial of Docetaxel With Perifosine

Phase 1
Completed
Conditions
Neoplasms
Interventions
Drug: Perifosine
Drug: Docetaxel
Drug: Prednisone
First Posted Date
2006-11-14
Last Posted Date
2014-02-13
Lead Sponsor
AEterna Zentaris
Target Recruit Count
39
Registration Number
NCT00399087
Locations
🇺🇸

Investigative Site, Johnson City, Tennessee, United States

Phase I Perifosine and Gemcitabine Study

Phase 1
Completed
Conditions
Neoplasms
First Posted Date
2006-11-14
Last Posted Date
2014-02-13
Lead Sponsor
AEterna Zentaris
Target Recruit Count
19
Registration Number
NCT00398697

Phase II Study of Perifosine in Patients With Refractory and Relapsed Leukemia

Phase 2
Completed
Conditions
Leukemia
Interventions
Drug: perifosine
First Posted Date
2006-10-24
Last Posted Date
2018-03-14
Lead Sponsor
AEterna Zentaris
Target Recruit Count
19
Registration Number
NCT00391560

Trial of Two Schedules of Perifosine for Patients With Solid Tumors or Lymphomas

Phase 2
Completed
Conditions
Lymphomas
Tumors
Interventions
Drug: Perifosine
First Posted Date
2006-10-18
Last Posted Date
2018-03-07
Lead Sponsor
AEterna Zentaris
Target Recruit Count
558
Registration Number
NCT00389077

Efficacy of Perifosine Alone and in Combination With Dexamethasone for Patients With Multiple Myeloma

Phase 2
Completed
Conditions
Multiple Myeloma
Interventions
Drug: perifosine
Drug: dexamethasone
First Posted Date
2006-09-13
Last Posted Date
2018-02-28
Lead Sponsor
AEterna Zentaris
Target Recruit Count
67
Registration Number
NCT00375791
Locations
🇺🇸

Investigative Site, Charlottesville, Virginia, United States

7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes

First Posted Date
2006-03-13
Last Posted Date
2013-09-30
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
30
Registration Number
NCT00301938
Locations
🇺🇸

University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy